Compugen
Update in progressCGEN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Compugen Ltd. is a clinical‑stage immuno‑oncology company with operations in Israel, the U.S., and Europe. Its pipeline includes COM701 (anti‑PVRIG) and COM902 (anti‑TIGIT) in Phase 1 for solid tumors, alone or with PVRIG/PD‑1 or PVRIG/TIGIT; Bapotulimab (anti‑ILDR2) in Phase I for naïve HNSCC; Rilvegostomig (anti‑PD‑1/TIGIT) in Phase III for NSCLC; COM503 (IL‑18BP blocker) in preclinical. Partnerships: BMS, AstraZeneca, Gilead. Founded 1993; HQ Holon, Israel.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!